• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

May 5, 2015

AJHP Explores Trends in Increased US Drug Spending

Growth will continue in 2015, with specialty pharmacies playing a more crucial role.

PRESS RELEASE

Bethesda, MD—A wave of innovation in specialty medications that caused U.S. prescription drug spending to spike significantly in 2014 is examined in three separate articles in the May 1 issue of the American Journal of Health-System Pharmacy (AJHP). The articles provide a deeper look into the factors driving drug expenditures and the increasing role of specialty pharmacies.

A special feature analyzes trends in pharmaceutical spending and presents projections for 2015, including nonfederal hospital and clinic settings. Using data from IMS Health, the authors analyze 2014 drug expenditures by sector and by drug and drug class, and explore factors that may impact future drug spending, such as new drug approvals and patent expirations. They conclude that spending will increase in 2015 but 7 to 9 percent across all settings, by 12 to 14 percent in clinics, and by 5 to 7 percent in hospitals.

The authors also note that spending growth will be driven more and more by specialty drugs—those that have high cost, are used to treat complex or rare diseases, have complicated manufacturing processes, are biological in origin, have special administration, monitoring, shipping and storage requirements, and/or need risk evaluation and mitigation strategies.

“Since most specialty drugs are still widely available to hospitals and clinics, important opportunities exist for creating outpatient specialty pharmacies in therapeutic categories that are relevant to the health system,” the article’s authors stress. “These new outpatient operations have the potential to improve medication access for patients, ensure better continuity of care and integration, improve patient outcomes, and provide a new revenue stream.”

The May 1 issue of AJHP contains an editorial on the dilemma posed by increasingly difficult access to specialty medications and what it means for pharmacists, authored by Rebekah Hanson, Pharm.D., BCPS, BCACP, clinical pharmacist and an assistant professor at the University of Illinois at Chicago College of Pharmacy.

“Pharmacists can create a truly collaborative, innovative, and comprehensive approach to specialty drug management that ensures patients have the ability to take advantage of life-changing therapies,” says Dr. Hanson. “They can prioritize specialty drug management programs within their institutions, inform government payers about the impact medication access has on providing value-based healthcare, and strategize with payers and manufacturers on ways to improve access.”

A Chief Pharmacy Officer Perspectives article in the May 1 issue also provides pharmacy decision-makers with an overview of the benefits of developing their own specialty pharmacy programs, issues to consider before undertaking one, and tips for successful implementation.

“By offering a specialty pharmacy program, a health system has the unique opportunity to connect with complex patient populations with life-long diseases at least monthly, developing a much stronger bond with those patients,” the article’s authors point out. “This provides a higher level of service and customer satisfaction, along with a higher level of care.”

Bethesda, MD—A wave of innovation in specialty medications that caused U.S. prescription drug spending to spike significantly in 2014 is examined in three separate articles in the May 1 issue of the American Journal of Health-System Pharmacy (AJHP). The articles provide a deeper look into the factors driving drug expenditures and the increasing role of specialty pharmacies.

A special feature analyzes trends in pharmaceutical spending and presents projections for 2015, including nonfederal hospital and clinic settings. Using data from IMS Health, the authors analyze 2014 drug expenditures by sector and by drug and drug class, and explore factors that may impact future drug spending, such as new drug approvals and patent expirations. They conclude that spending will increase in 2015 but 7 to 9 percent across all settings, by 12 to 14 percent in clinics, and by 5 to 7 percent in hospitals.

The authors also note that spending growth will be driven more and more by specialty drugs—those that have high cost, are used to treat complex or rare diseases, have complicated manufacturing processes, are biological in origin, have special administration, monitoring, shipping and storage requirements, and/or need risk evaluation and mitigation strategies.

“Since most specialty drugs are still widely available to hospitals and clinics, important opportunities exist for creating outpatient specialty pharmacies in therapeutic categories that are relevant to the health system,” the article’s authors stress. “These new outpatient operations have the potential to improve medication access for patients, ensure better continuity of care and integration, improve patient outcomes, and provide a new revenue stream.”

The May 1 issue of AJHP contains an editorial on the dilemma posed by increasingly difficult access to specialty medications and what it means for pharmacists, authored by Rebekah Hanson, Pharm.D., BCPS, BCACP, clinical pharmacist and an assistant professor at the University of Illinois at Chicago College of Pharmacy.

“Pharmacists can create a truly collaborative, innovative, and comprehensive approach to specialty drug management that ensures patients have the ability to take advantage of life-changing therapies,” says Dr. Hanson. “They can prioritize specialty drug management programs within their institutions, inform government payers about the impact medication access has on providing value-based healthcare, and strategize with payers and manufacturers on ways to improve access.”

A Chief Pharmacy Officer Perspectives article in the May 1 issue also provides pharmacy decision-makers with an overview of the benefits of developing their own specialty pharmacy programs, issues to consider before undertaking one, and tips for successful implementation.

“By offering a specialty pharmacy program, a health system has the unique opportunity to connect with complex patient populations with life-long diseases at least monthly, developing a much stronger bond with those patients,” the article’s authors point out. “This provides a higher level of service and customer satisfaction, along with a higher level of care.”

- See more at: http://www.ashp.org/menu/AboutUs/ForPress/PressReleases/PressRelease.aspx?id=855#sthash.0RoejKjW.dpuf

Bethesda, MD—A wave of innovation in specialty medications that caused U.S. prescription drug spending to spike significantly in 2014 is examined in three separate articles in the May 1 issue of the American Journal of Health-System Pharmacy (AJHP). The articles provide a deeper look into the factors driving drug expenditures and the increasing role of specialty pharmacies.

A special feature analyzes trends in pharmaceutical spending and presents projections for 2015, including nonfederal hospital and clinic settings. Using data from IMS Health, the authors analyze 2014 drug expenditures by sector and by drug and drug class, and explore factors that may impact future drug spending, such as new drug approvals and patent expirations. They conclude that spending will increase in 2015 but 7 to 9 percent across all settings, by 12 to 14 percent in clinics, and by 5 to 7 percent in hospitals.

The authors also note that spending growth will be driven more and more by specialty drugs—those that have high cost, are used to treat complex or rare diseases, have complicated manufacturing processes, are biological in origin, have special administration, monitoring, shipping and storage requirements, and/or need risk evaluation and mitigation strategies.

“Since most specialty drugs are still widely available to hospitals and clinics, important opportunities exist for creating outpatient specialty pharmacies in therapeutic categories that are relevant to the health system,” the article’s authors stress. “These new outpatient operations have the potential to improve medication access for patients, ensure better continuity of care and integration, improve patient outcomes, and provide a new revenue stream.”

The May 1 issue of AJHP contains an editorial on the dilemma posed by increasingly difficult access to specialty medications and what it means for pharmacists, authored by Rebekah Hanson, Pharm.D., BCPS, BCACP, clinical pharmacist and an assistant professor at the University of Illinois at Chicago College of Pharmacy.

“Pharmacists can create a truly collaborative, innovative, and comprehensive approach to specialty drug management that ensures patients have the ability to take advantage of life-changing therapies,” says Dr. Hanson. “They can prioritize specialty drug management programs within their institutions, inform government payers about the impact medication access has on providing value-based healthcare, and strategize with payers and manufacturers on ways to improve access.”

A Chief Pharmacy Officer Perspectives article in the May 1 issue also provides pharmacy decision-makers with an overview of the benefits of developing their own specialty pharmacy programs, issues to consider before undertaking one, and tips for successful implementation.

“By offering a specialty pharmacy program, a health system has the unique opportunity to connect with complex patient populations with life-long diseases at least monthly, developing a much stronger bond with those patients,” the article’s authors point out. “This provides a higher level of service and customer satisfaction, along with a higher level of care.”

- See more at: http://www.ashp.org/menu/AboutUs/ForPress/PressReleases/PressRelease.aspx?id=855#sthash.0RoejKjW.dpuf

Bethesda, MD—A wave of innovation in specialty medications that caused U.S. prescription drug spending to spike significantly in 2014 is examined in three separate articles in the May 1 issue of the American Journal of Health-System Pharmacy (AJHP). The articles provide a deeper look into the factors driving drug expenditures and the increasing role of specialty pharmacies.

A special feature analyzes trends in pharmaceutical spending and presents projections for 2015, including nonfederal hospital and clinic settings. Using data from IMS Health, the authors analyze 2014 drug expenditures by sector and by drug and drug class, and explore factors that may impact future drug spending, such as new drug approvals and patent expirations. They conclude that spending will increase in 2015 but 7 to 9 percent across all settings, by 12 to 14 percent in clinics, and by 5 to 7 percent in hospitals.

The authors also note that spending growth will be driven more and more by specialty drugs—those that have high cost, are used to treat complex or rare diseases, have complicated manufacturing processes, are biological in origin, have special administration, monitoring, shipping and storage requirements, and/or need risk evaluation and mitigation strategies.

“Since most specialty drugs are still widely available to hospitals and clinics, important opportunities exist for creating outpatient specialty pharmacies in therapeutic categories that are relevant to the health system,” the article’s authors stress. “These new outpatient operations have the potential to improve medication access for patients, ensure better continuity of care and integration, improve patient outcomes, and provide a new revenue stream.”

The May 1 issue of AJHP contains an editorial on the dilemma posed by increasingly difficult access to specialty medications and what it means for pharmacists, authored by Rebekah Hanson, Pharm.D., BCPS, BCACP, clinical pharmacist and an assistant professor at the University of Illinois at Chicago College of Pharmacy.

“Pharmacists can create a truly collaborative, innovative, and comprehensive approach to specialty drug management that ensures patients have the ability to take advantage of life-changing therapies,” says Dr. Hanson. “They can prioritize specialty drug management programs within their institutions, inform government payers about the impact medication access has on providing value-based healthcare, and strategize with payers and manufacturers on ways to improve access.”

A Chief Pharmacy Officer Perspectives article in the May 1 issue also provides pharmacy decision-makers with an overview of the benefits of developing their own specialty pharmacy programs, issues to consider before undertaking one, and tips for successful implementation.

“By offering a specialty pharmacy program, a health system has the unique opportunity to connect with complex patient populations with life-long diseases at least monthly, developing a much stronger bond with those patients,” the article’s authors point out. “This provides a higher level of service and customer satisfaction, along with a higher level of care.”

- See more at: http://www.ashp.org/menu/AboutUs/ForPress/PressReleases/PressRelease.aspx?id=855#sthash.0RoejKjW.dpuf

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
Plaque buildup in artery | Image Credit: © SK imagine - stock.adobe.com
May 8th 2025

Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
U.S. House of Representatives, Washington, DC USA
May 8th 2025

Coalition of Pharmacy Organizations Urges Congress to Pass ECAPS Legislation

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
GLP-1 and Side Effects newspaper headlines with magnifying glass
May 8th 2025

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Luke Halpern, Assistant Editor
Wegovy injection pen | Image Credit: © Patrick Bay Damsted - stock.adobe.com
May 7th 2025

GLP-1 Drugs Show Promise in Lowering Health Care Costs, Report Says

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Plaque buildup in artery | Image Credit: © SK imagine - stock.adobe.com
May 8th 2025

Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
U.S. House of Representatives, Washington, DC USA
May 8th 2025

Coalition of Pharmacy Organizations Urges Congress to Pass ECAPS Legislation

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
GLP-1 and Side Effects newspaper headlines with magnifying glass
May 8th 2025

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Luke Halpern, Assistant Editor
Wegovy injection pen | Image Credit: © Patrick Bay Damsted - stock.adobe.com
May 7th 2025

GLP-1 Drugs Show Promise in Lowering Health Care Costs, Report Says

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.